Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18522846 | 1.00 | KDM4E (0.46) | KDM4ESIGMAR1NPC1RAB9ALTB4R | |
| Hydrochloric Acid SCHEMBL18489871 | 0.99 | KDM4E (0.45) | KDM4ESIGMAR1NPC1RAB9ALTB4R | |
| Hydrochloric Acid SCHEMBL17203024 | 0.99 | KDM4E (0.45) | KDM4ESIGMAR1NPC1RAB9ALTB4R | |
| SCHEMBL18522832 | 0.90 | KDM4E (0.58) | KDM4ESIGMAR1LTB4RLTB4R2ALDH1A1 | |
| SCHEMBL16202140 | 0.90 | KDM4E (0.58) | KDM4ESIGMAR1LTB4RLTB4R2ALDH1A1 | |
| SCHEMBL18511507 | 0.89 | KDM4E (0.47) | KDM4ESIGMAR1LTB4RLTB4R2MAOB | |
| SCHEMBL18511509 | 0.89 | KDM4E (0.47) | KDM4ESIGMAR1NPC1RAB9ALTB4R | |
| SCHEMBL18522836 | 0.86 | KDM4E (0.44) | KDM4ESIGMAR1LTB4RLTB4R2MAOB | |
| SCHEMBL18489859 | 0.86 | KDM4E (0.44) | KDM4ESIGMAR1LTB4RLTB4R2MAOB | |
| SCHEMBL18522948 | 0.82 | KDM4E (0.41) | KDM4ESIGMAR1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-01-11 | — | — | US | disclosed |
| US-20210038738-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2021-02-11 | — | — | US | disclosed |
| US-10912841-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2021-02-09 | — | — | US | disclosed |
| US-10858423-B2 | Composition for the treatment of IGF-1R expressing cancer | PIERRE FABRE MEDICAMENT (FR) | 2020-12-08 | — | — | US | disclosed |
| US-20200270352-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2020-08-27 | — | — | US | disclosed |
| US-10633448-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2020-04-28 | — | — | US | disclosed |
| EP-3607996-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2020-02-12 | — | — | EP | disclosed |
| EP-3134125-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2019-10-09 | — | — | EP | disclosed |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2019-06-11 | — | — | US | disclosed |
| EP-3134124-B1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2019-02-20 | — | — | EP | disclosed |
| US-9669106-B2 | Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2017-06-06 | — | — | US | disclosed |
| US-9669106-B2 | Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2017-06-06 | — | — | US | disclosed |
| WO-2017072196-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-05-04 | — | — | WO | disclosed |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-04-27 | — | — | US | disclosed |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-04-27 | — | — | US | disclosed |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
| US-20170043031-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858423-B2 | Composition for the treatment of IGF-1R expressing cancer | IGF1R, IGFBP1, IGFBP5 | KDM4E 1718/4885SIGMAR1 3177/4885NPC1 4170/4885 |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | KDM4E 1659/4885SIGMAR1 4684/4885NPC1 379/4885 |
| US-20200270352-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | IGF1R, IGFBP1, IGFBP5 | KDM4E 1679/4885SIGMAR1 2924/4885NPC1 769/4885 |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | AURKC, AURKA, EGFR | KDM4E 678/4885SIGMAR1 4578/4885NPC1 4292/4885 |
| US-10912841-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | KDM4E 2202/4885SIGMAR1 4045/4885NPC1 466/4885 |
| US-10633448-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | IGF1R, IGFBP1, IGFBP5 | KDM4E 1679/4885SIGMAR1 2924/4885NPC1 769/4885 |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | KDM4E 2202/4885SIGMAR1 4045/4885NPC1 466/4885 |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DAD1, DDOST, KRTCAP2 | KDM4E 2260/4885SIGMAR1 4112/4885NPC1 742/4885 |
| US-20170043031-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | IGF1R, IGFBP1, IGFBP5 | KDM4E 1679/4885SIGMAR1 2924/4885NPC1 769/4885 |
| US-20210038738-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | DDOST, DAD1, KRTCAP2 | KDM4E 2068/4885SIGMAR1 4163/4885NPC1 508/4885 |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | KRTCAP2, DDOST, DAD1 | KDM4E 1659/4885SIGMAR1 4684/4885NPC1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.